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the Netherlands; Bern, Switzerland; Buenos Aires, Argentina; and Prague, Czech RepublicObjectives This study sought to assess the clinical safety and effectiveness of the Resolute
zotarolimus-eluting stent (R-ZES) in patients with in-stent restenosis (ISR) from 2 large trials.
Background ISR treatment is associated with higher rates of subsequent cardiac events compared
with treatment of de novo lesions. Although drug-eluting stents (DES) are an option, second-
generation DES are largely untested in the treatment of ISR.
Methods A total of 3,489 patients were pooled from the RAC (RESOLUTE All Comers) trial and the
RESOLUTE International (RINT) registry. Two-year clinical endpoints included clinically driven target
lesion revascularization (TLR), target lesion failure (TLF), cardiac death (CD), target vessel myocardial
infarction (TVMI), combined CD or TVMI (CD/TVMI), and Academic Research Consortium deﬁnite and
probable stent thrombosis (ST).
Results Overall, 281 patients (8.1%) received an R-ZES for ISR. Two-year TLR and TLF rates were
signiﬁcantly higher in ISR patients than in non-ISR patients (TLR: 12.7% vs. 4.3%, p ¼ 0.003; TLF: 17.4%
vs. 9.4%, p ¼ 0.007); however, the CD/TVMI rate was not (6.9% vs. 6.1%, p ¼ 0.711). Seven ISR patients
had ST. Two-year outcomes by ISR stent type were similar: bare-metal stent (BMS)-ISR TLR was 12.5%
and TLF was 17.2%; DES-ISR TLR was 13.0% and TLF was 18.8%. CD/TVMI was 7.3% and 7.2% for
BMS-ISR and DES-ISR, respectively.
Conclusions Using R-ZES to treat ISR appears equally safe in BMS-ISR and DES-ISR, with CD/TVMI rates
comparable to 2-year outcomes in other clinical trials. Although revascularization rates are still higher
in ISR lesions, the R-ZES offers an effective alternative for treatment of BMS-ISR and DES-ISR.
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906Drug-eluting stents (DES) have substantially reduced
revascularization rates in de novo lesions, and outcomes
have further improved with the advent of second-
generation DES. In-stent restenosis (ISR) is historically
considered the Achilles heel of percutaneous coronary
interventions (PCI) and has been associated with worse
outcomes than treatment of de novo lesions. Previous
studies have reported target lesion revascularization (TLR)
rates around 15% and target vessel revascularization (TVR)
rates as high as 22% at 1 year following retreatment of
a restenotic lesion (1–5). Moreover, an ISR after DES
implantation is regarded as an exceedingly challenging
lesion with an even worse outcome than bare-metal stent
(BMS)-ISR. Although there are promising observations
with drug-eluting balloons (DEB) (5–11) and with certain
ﬁrst-generation DES for treatment of ISR (1), the optimaloccasional speaker’s honoraria from B
support from Biotronik. Dr. Silber
consultant fees from Medtronic. Dr. W
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Abbreviations
and Acronyms
BMS = bare-metal stent(s)
CD = cardiac death
DES = drug-eluting stent(s)
ISR = in-stent restenosis
MI = myocardial infarction
PCI = percutaneous coronary
intervention
R-ZES = Resolute
zotarolimus-eluting stent(s)
ST = stent thrombosis
TLF = target lesion failure
TLR = target lesion
revascularization
TVMI = target vessel
myocardial infarction
TVR = target vesseltreatment modality of ISR has
yet to be established. In partic-
ular, data about ISR treatment
with new-generation DES are
missing.
The Resolute zotarolimus-
eluting stent (R-ZES) (Medtronic
Vascular, Santa Rosa, Califor-
nia) is a contemporary thin-strut
cobalt-chromium, open-cell stent
with a thin biocompatible coating
(BioLinx, Medtronic Vascular).
The R-ZES has been tested in
a global clinical trial program of
randomized and observational
studies in well-deﬁned patient
subgroups using similar rigorous
methodologies to provide a com-
prehensive assessment of DES
performance in a wide variety of
clinical and anatomic conditions.In aggregate, the studies revealed an excellent efﬁcacy and
safety of the R-ZES, which is at least noninferior to the
everolimus-eluting stent (12–15).
The RAC (RESOLUTE All Comers) and RINT
(RESOLUTE International) studies accrued a high
proportion of patients with complex clinical and lesion
characteristics, including ISR. Here, we present a pooled
analysis of RAC and RINT patients with an ISR treated
with the R-ZES to assess the clinical safety and effectiveness
of the R-ZES in this population. Considering the possibility
of a late catch-up following treatment of ISR, which was
revascularizationoston Scientiﬁc. Dr. Toelg has received grant
has received grant and travel support and
indecker is a consultant for Boston Scientiﬁc,
ensors; and his institution has received research
Scientiﬁc, Biosensors, Cordis, Medtronic, and
on an advisory board and is a consultant formost striking after brachytherapy (16,17), our analysis
comprised a follow-up period of 2 years. An additional
analysis compared the performance of the R-ZES depend-
ing on the type of restenosis either following BMS or DES
implantation.
Methods
Patients and protocol. The design of the RAC and RINT
studies, which were both large, multicenter, open-label,
prospective clinical trials with minimal exclusion criteria,
have been previously described (14,18). Brieﬂy, the RAC
trial was a randomized, noninferiority study that compared
the R-ZES to the Xience V everolimus-eluting stent
(Abbott Vascular, Santa Clara, California) in patients with
chronic, stable coronary artery disease or acute coronary
syndromes. To be included in the study, patients had to have
at least 1 coronary artery stenosis >50% with a reference
diameter of 2.25 to 4.0 mm, and there were no restrictions
regarding the total number of treated lesions, treated vessels,
lesion length, or number of stents implanted. The RINT
registry was an observational study of patients with symp-
tomatic coronary artery disease, all of whom received at least
1 R-ZES. Like the RAC trial, the RINT registry had no
restrictions on clinical indication (stable angina vs. acute
coronary syndromes), number of treated vessels and lesions,
lesion type, or lesion length. Both studies were also similar in
their exclusion criteria, post-procedure dual antiplatelet
therapy, and scheduled follow-up. Exclusion criteria
included a known intolerance to a study drug, metal alloys,
or contrast media; planned surgery within 6 months after the
index procedure; childbearing potential; or concurrent
participation in another trial that could affect the study
procedures. Post-procedure dual antiplatelet therapy con-
sisted of lifelong daily aspirin (75 mg) and daily clopi-
dogrel (75 mg) for at least 6 months. Patient follow-up was
performed by telephone or clinic visit at 1, 6, 12, and
24 months and is planned to continue annually for 5 years.
Clinical endpoints and deﬁnitions. Similar endpoint deﬁni-
tions were used in the RAC trial and the RINT registry and
have been previously described (14,18). The same deﬁni-
tions were used for the endpoints assessed in the present
pooled analysis. The principal endpoints for the pooled
analysis were: 1) target lesion failure (TLF), deﬁned as
a composite of cardiac death (CD), target vessel myocardial
infarction (TVMI), or clinically driven TLR; and 2)
combined probable and deﬁnite stent thrombosis (ST), as
deﬁned by the Academic Research Consortium. Using theMedtronic. Dr. Widimsky receives occasional speaker’s honoraria from Medtronic.
All other authors have reported that they have no relationships relevant to the
contents of this paper to disclose.
Manuscript received September 10, 2012; revised manuscript received April 12, 2013,
accepted April 19, 2013.
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907same endpoints, an additional analysis was performed to
evaluate the outcomes of ISR patients by stent type (BMS
vs. DES). Events as adjudicated in the RAC trial and RINT
registry were utilized for the present pooled analysis, and
endpoints were assessed at 1 and 2 years.
Statistical analysis. All data were analyzed according to the
intention-to-treat principle. Descriptive statistics were
determined for baseline patient and lesion characteristics,
and data are presented as percentage or mean  SD. The
clinical outcomes were compared with propensity score–
adjusted p values to adjust for differences in patient cha-
racteristics between groups (ISR vs. non-ISR, and BMS
vs. DES-ISR). Propensity scores were calculated using
logistic regression with treatment group (ISR vs. non-ISR)
as the dependent variable and the following baseline
characteristics as the independent variables: age, sex,
current smoker, prior PCI, hyperlipidemia, diabetes, hy-
pertension, prior myocardial infarction (MI), prior coro-
nary artery bypass grafting (CABG), unstable angina or
MI, target vessel¼left anterior descending coronary artery
(LAD), American College of Cardiology/American Heart
Association lesion class B2 or C lesion, moderate/severe
calciﬁcation, bend >45, TIMI (Thrombolysis In Myo-
cardial Infarction) ﬂow grade 3, reference vessel diameter
(RVD), lesion length, and pre-procedure percent diameter
stenosis. Multivariate predictors were calculated using
stepwise logistic regression. Variables selected for the
multivariate analysis were those with a p value 0.2 in the
simple logistic regression analysis. In the multiple logistic
regression analysis, only those with a p value of 0.1 were
kept in the analysis. A p value of <0.05 was considered
statistically signiﬁcant.Table 1. Baseline Patient Demographic Characteristics
Baseline Characteristics
Resolute ISR
(n ¼ 281)
Age, yrs 65.3  10.5 (281)
Male 77.6 (218/281)
Diabetes mellitus 31.0 (87/281)
Insulin dependent 12.1 (34/281)
Current smoker 14.6 (41/281)
Hyperlipidemia 81.1 (228/281)
History of hypertension 79.0 (222/281)
Family history of CAD 36.2 (79/218)
Prior myocardial infarction 53.9 (151/280)
Prior PCI 100.0 (281/281)
Prior CABG 12.5 (35/281)
Cardiac status
Stable angina 42.7 (120/281)
Unstable angina 30.6 (86/281)
Myocardial infarction 16.7 (47/281)
Values are mean  SD (N) or % (n/N).
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; ISRThe cumulative incidence of events was analyzed using
the Kaplan-Meier method and is shown with 2-sided 95%
conﬁdence intervals and log-rank p values. For each
endpoint, treatment groups were compared on time to event
using Cox proportional hazards regression. All statistical
analyses were performed using SAS version 9.1 or higher
(SAS Institute, Cary, North Carolina).
Results
A total of 3,489 patients were included in the pooled
analysis. Of these patients, complete data were available for
3,475. Overall, 3,194 patients received an R-ZES to treat
a non-ISR lesion, whereas 281 patients (8.1%) received an
R-ZES to treat an ISR lesion (91 patients from the RAC
trial and 190 patients from the RINT registry). At 1 year,
clinical follow-up data were available in 281 ISR patients
and 3,169 non-ISR patients; at 2 years, clinical follow-up
data were available in 276 ISR patients and 3,127 non-ISR
patients. Table 1 compares the baseline demographics of
the ISR patients and non-ISR patients. In summary, ISR
patients were older, not current smokers, and had more
hypertension, hyperlipidemia, insulin-dependent diabetes
mellitus, previous MI, and prior CABG. Patients with ISR
more often underwent coronary intervention for stable
angina than non-ISR patients; nonetheless, nearly half of the
ISR cohort presented with an acute coronary syndrome.
Pre- and post-procedure lesion characteristics for the ISR
and non-ISR patients are presented in Table 2. For both
groups, the most frequent lesion location was the LAD,
followed by the right coronary artery (RCA) and left
circumﬂex artery; however, ISR patients had more RCAResolute Non-ISR
(n ¼ 3,194) p Value
63.6  11.1 (3,194) 0.015
77.4 (2,472/3,194) 0.943
27.9 (890/3,194) 0.268
8.4 (268/3,194) 0.034
25.8 (825/3,194) <0.001
62.4 (1,993/3,194) <0.001
68.0 (2,173/3,194) <0.001
32.0 (809/2,530) 0.197
25.3 (803/3,178) <0.001
24.4 (778/3,194) <0.001
8.5 (272/3,194) 0.026
<0.001
35.4 (1,132/3,194)
23.4 (746/3,194)
32.6 (1,042/3,194)
¼ in-stent restenosis; PCI ¼ percutaneous coronary intervention.
Table 2. Pre- and Post-Procedure Lesion Characteristics
Characteristics
Resolute ISR
(n ¼ 281 Patients,
410 Lesions)
Resolute Non-ISR
(n ¼ 3,194 Patients,
4,614 Lesions) p Value
Vessel location <0.001
LAD 36.7 (141/384) 43.9 (1,939/4,412)
LCX 22.9 (88/384) 24.0 (1,058/4,412)
RCA 34.6 (133/384) 28.7 (1,267/4,412)
LMCA 1.6 (6/384) 1.9 (82/4,412)
SVG 3.6 (14/384) 1.4 (60/4,412)
LIMA 0.5 (2/384) 0.1 (6/4,412)
ISR after BMS* 70.8 (199/281) 0.0 (0/3,194) NA
ISR after DES* 26.0 (73/281) 0.0 (0/3,194) NA
Pre-procedure thrombus 5.1 (19/370) 10.2 (438/4,286) 0.002
Lesion class B2/C 59.7 (227/380) 64.4 (2,829/4,392) 0.068
RVD, mmy 2.92  0.56 (362) 2.84  0.51 (4,137) 0.005
MLD, mmy 0.69  0.50 (380) 0.62  0.49 (4,365) 0.005
Lesion length, mmy 18.0  12.9 (361) 16.6  10.1 (4,113) 0.040
Stent diameter, mm 3.2  0.5 (281) 3.1  0.5 (3,194) 0.002
Stent length, mm 22.1  6.4 (281) 20.9  6.6 (3,194) 0.005
Pre-procedure % diameter stenosisy 75.5  17.8 (380) 77.6  17.6 (4,365) 0.022
Post-procedure % diameter stenosisy 10.7  14.2 (383) 9.9  13.9 (4,397) 0.220
Values are % (n/N) or mean  SD (N). *The original stent type was unknown in 9 ISR patients. yFor RESOLUTE International, angiographic
measurements are site reported.
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); ISR ¼ in-stent restenosis; LAD ¼ left anterior descending coronary artery; LCX ¼ left
circumﬂex coronary artery; LIMA ¼ left internal mammary artery; LMCA ¼ left main coronary artery; MLD ¼ minimum luminal diameter; RCA ¼ right
coronary artery; RVD ¼ reference vessel diameter; SVG ¼ saphenous vein graft.
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908lesions and fewer LAD lesions than did non-ISR patients.
Both groups had similarly complex, class B2/C lesions,
although lesions were longer in ISR patients. Pre-procedureTable 3. Clinical Outcomes at 1 and 2 Years
Endpoints
1 Year
Resolute ISR
(RAC and RINT)
(n ¼ 281)
Resolute Non-ISR
(RAC and RINT)
(n ¼ 3,169)
TVF 11.4 (32/281) 7.6 (240/3,169)
TLF 10.7 (30/281) 6.9 (219/3,169)
Death 2.8 (8/281) 2.1 (66/3,169)
Cardiac death 1.8 (5/281) 1.4 (43/3,169)
TVMI 2.8 (8/281) 3.5 (110/3,169)
Cardiac death or TVMI 3.9 (11/281) 4.6 (146/3,169)
Clinically driven TLR 7.5 (21/281) 3.1 (97/3,169)
Clinically driven TVR 8.5 (24/281) 3.8 (122/3,169)
MACEy 12.1 (34/281) 7.8 (248/3,169)
Stent thrombosis, ARC def/prob 2.1 (6/281) 1.0 (32/3,169)
Early (30 days) 0.7 (2/281) 0.9 (27/3,169)
Late (>30 and 360 days) 1.4 (4/281) 0.2 (6/3,169)
Very late (>360 days) NA NA
Values are % (n/N). *p value is adjusted to propensity score with the following baseline variables as in
lipidemia, diabetes, hypertension, prior myocardial infarction, prior bypass surgery, unstable angina or
bend >45 , Thrombolysis In Myocardial Infarction ﬂow grade 3, reference vessel diameter, lesion length,
non–Q-wave), emergent coronary artery bypass surgery, or repeat clinically indicated target-lesion per
ARC ¼ Academic Research Consortium; MACE ¼ major adverse cardiac events; RAC ¼ RESOLUTE
TVF ¼ target vessel failure; TVMI ¼ target vessel myocardial infarction; TVR ¼ target vessel revascularithrombus was present twice as often in non-ISR patients.
The RVD and minimum lumen diameter were larger and
the percent diameter stenosis was smaller in ISR patients2 Years
p Value*
Resolute ISR
(RAC and RINT)
(n ¼ 276)
Resolute Non-ISR
(RAC and RINT)
(n ¼ 3,127) p Value*
0.155 18.8 (52/276) 10.6 (331/3,127) 0.017
0.096 17.4 (48/276) 9.4 (294/3,127) 0.007
0.410 5.4 (15/276) 3.9 (122/3,127) 0.456
0.304 2.9 (8/276) 2.6 (81/3,127) 0.565
0.507 4.7 (13/276) 3.8 (120/3,127) 0.905
0.820 6.9 (19/276) 6.1 (192/3,127) 0.711
0.054 12.7 (35/276) 4.3 (135/3,127) 0.003
0.097 14.5 (40/276) 5.7 (179/3,127) 0.011
0.107 19.9 (55/276) 11.1 (347/3,127) 0.011
0.269 2.5 (7/276) 1.2 (37/3,127) 0.332
0.974 0.7 (2/276) 0.9 (27/3,127) 0.980
0.185 1.4 (4/276) 0.2 (6/3,127) 0.183
NA 0.4 (1/276) 0.2 (5/3,127) 0.889
dependent variables: age, sex, current smoker, prior percutaneous coronary intervention, hyper-
myocardial infarction, left anterior descending artery, B2/C lesion, moderate/severe calciﬁcation,
and percent diameter stenosis. yMACE is a composite of death, myocardial infarction (Q-wave and
cutaneous or surgical revascularization.
All Comers trial; RINT ¼ RESOLUTE International registry; TLR ¼ target lesion revascularization;
zation; other abbreviations as in Table 2.
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909compared with non-ISR patients. There was no statistically
signiﬁcant difference in the post-procedure percent diameter
stenosis between the 2 groups. Within the ISR group, ISR
occurred almost 3 times more often in lesions treated with
a BMS than in those treated with a DES.
Clinical outcomes. Table 3 summarizes the clinical
outcomes at 1 and 2 years of ISR and non-ISR patients
treated with an R-ZES. At 1 year, there were no statistically
signiﬁcant differences in the clinical outcomes between the
2 groups, although a numerical difference was observed in
the rate of overall ST (2.1% vs. 1.0%, p ¼ 0.269) and late
ST (1.4% vs. 0.2%, p ¼ 0.185) in the ISR and non-ISR
cohorts, respectively. At 2 years, however, ISR patients
experienced signiﬁcantly more TVF (18.8% vs. 10.6%,
p ¼ 0.017), TLF (17.4% vs. 9.4%, p ¼ 0.007), clinically
driven TLR (12.7% vs. 4.3%, p ¼ 0.003), clinically driven
TVR (14.5% vs. 5.7%, p ¼ 0.011), and major adverse
cardiac events (19.9% vs. 11.1%, p ¼ 0.011). The ST rate
was numerically higher in the ISR group (2.5% vs. 1.2%,
respectively, p ¼ 0.332), with a marginally signiﬁcant log-
rank p value of 0.058 in the Kaplan-Meier analysis.
Nonetheless, rates of death, CD, and TVMI remained
similar between the 2 groups. Kaplan-Meier curves illus-
trating the time to event occurrence for the study’s principal
endpoints are presented in Figures 1A to 1D.
The proportion of patients on dual antiplatelet therapy at
6 months and 1 year in both the ISR and non-ISR groups
was similar (95.3% vs. 95% and 89.4% vs. 89%, respectively).
At 2 years, only 41% vs. 35.1% were on dual antiplatelet
therapy, but the vast majority of patients (97.3% vs. 95.1%)
were receiving aspirin.
Multivariate predictors of TLF. Multivariate analysis identi-
ﬁed several independent predictors of TLF inR-ZES–treated
patients at 2 years (Table 4). In the total pooled population,
predictors of TLF included ISR, prior CABG, vessel bend
45, previous MI, unstable angina, and pre-procedure
RVD. In the ISR subgroup, predictors of TLF included prior
CABG, unstable angina, and patient age.
Performance of the R-ZES for treatment of a BMS or DES
restenosis. Baseline characteristics were similar between
patients with a BMS-ISR or DES-ISR treated with an R-
ZES (Table 5). Clinical outcomes at 2 years according to
ISR stent type were similar (Table 6): for the BMS-ISR
subgroup, the rate of TLR was 12.5%, and the rate of TLF
was 17.2%; for the DES-ISR subgroup, the rate of TLR was
13.0%, and TLF was 18.8%. Combined CD or MI rates
were 7.3% and 7.2% for BMS-ISR and DES-ISR, respec-
tively. Six ST events occurred in the BMS-ISR subgroup,
and 1 event occurred in the DES-ISR subgroup.
Discussion
The occurrence of ISR remains a signiﬁcant limitation of
coronary stent implantation in daily practice. Although DEScan effectively reduce the incidence of ISR in a given lesion
and patient, the global burden of ISR is not reduced by DES
due to the increasing use of coronary stents and the higher
complexity of treated coronary anatomies.
We assessed one of the largest datasets on patients with
ISR from 2 prospective all-comer trials that were designed
with consistent deﬁnitions, adjudication methods, and data
collection. About 8% of the patients in the pooled analysis
presented with an ISR. The rate of ISR patients was lower
than in previous DES registries (19–22). The numbers of
ISR patients were disproportionally high in the alluded
registries, probably because restenotic lesions were regarded
as a preferable indication for DES implantation as long as
DES were not used in all patients without particular con-
traindications, which was the case in our cohort. Therefore,
our ISR ratio presumably represents a more adequate picture
of the contemporary ISR burden, of which approximately
one-quarter of the ISR patients had a restenosis after former
DES implantation.
Although patients with ISR more often underwent
coronary intervention for stable angina than did the non-
ISR patients, nearly half of the ISR cohort presented with an
acute coronary syndrome. The recognition that a consider-
able proportion of patients with ISR presented with an acute
coronary syndrome is in line with several previous reports,
which have disproved the original perception of ISR as
a benign clinical issue (3,23,24).
ISR may not only cause MIs, but it also has a higher
recurrence rate than de novo lesions, and treatment strate-
gies for ISR are by far less established than in other coronary
anatomies. Current guidelines recommend the use of cutting
or scoring balloons for lesion preparation followed by DEB
treatment or DES implantation (25,26). DES of the ﬁrst
generation were effective in the treatment of a restenosis
following BMS or DES (1,4,27–29). We present the ﬁrst
large cohort of patients undergoing ISR treatment with
a new-generation cobalt-chromium, thin strut, limus-eluting
stent, namely the Resolute stent, which releases zotarolimus
from a biocompatible polymer.
The principal ﬁnding of our investigation was that the
TLF rate nearly doubled in patients with ISR, compared
with non-ISR patients, and was mainly driven by a higher
TLR rate. The Kaplan-Meier curves of TLR rates divided
after 6 months and continuously separated thereafter.
Nonetheless, TLR rates of 7.5% after 12 months and 12.7%
after 2 years are still in a very reasonable range compared
with other studies (3,5,19,24,30). Moreover, PCI of ISR
with R-ZES was safe, with no excess of CD or TVMI
observed out to 2 years. Notably, the ST events were
numerically higher in ISR patients at 1 and 2 years, but the
difference did not reach statistical signiﬁcance. This was also
noted among the BMS-ISR compared with the DES-ISR
subgroup, with inadequate power to allow meaningful
comparison.
Figure 1. Kaplan-Meier Curves for the Study’s Principal Endpoints
Kaplan-Meier curves illustrating time to event occurrence for (A) target lesion failure (TLF); (B) composite occurrence of cardiac death and target vessel myocardial
infarction (TVMI). (C) clinically driven target lesion revascularization; and (D) stent thrombosis (probable/deﬁnite as deﬁned by the Academic Research Consortium).
ARC ¼ Academic Research Consortium; ISR ¼ in-stent restenosis; ST ¼ stent thrombosis; TLR ¼ target lesion revascularization.
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910The treatment of ISR patients and non-ISR patients with
R-ZES resulted in a similar acute angiographic success as
documented in a post-procedural diameter stenosis of some
10% in both cohorts. Thus, the higher TLF rate in the ISR
cohort was probably not the consequence of an under-
expansion of the R-ZES. There was also no obvious major
imbalance in risk factors for restenosis in the patient and
lesion characteristics of both groups. It rather appears that
the ISR per se carries a higher disposition for a TLF,
possibly due to the unique biology of an ISR. Consequently,
ISR was the strongest independent predictor for TLF in our
total study population.
Nevertheless, revascularization rates with R-ZES
compare favorably with other contemporary ISR trials
(3–5,15,19,21,24). Because longer observation periods are
missing in most ISR studies, a comparison of the RESO-
LUTE pooled data has been conﬁned to 9- and 12-month
revascularization rates. Regarding BMS-ISR, our TLR and
TVR rates are in line with the sirolimus-eluting stent group
in the ISAR-DESIRE (Intracoronary Stenting or Angio-
plasty for Restenosis Reduction: Drug-Eluting Stents forIn-Stent Restenosis) trial (8% TVR), the DEB group in the
PEPCAD II (Paclitaxel-Eluting PTCA-Balloon Catheter
in Coronary Artery Disease II) study (6% TLR), and the
ﬁndings in TAXUS V-ISR (Randomized Trial Evaluating
Slow-Release Formulation TAXUS Paclitaxel-Eluting
Coronary Stent in the Treatment of In-Stent Restenosis)
(10.5% TVR at 9 months) (1,5,29). Remarkably, the R-
ZES appears to be equally effective in patients with BMS-
ISR and with DES-ISR. Treatment of DES-ISR with
DEB or another DES was by far less successful in previous
studies. In PEPCAD-DES (6), treatment of DES-ISR with
DEB resulted in a TLR rate of 15.3% at 6 months. Similar
rates were observed in ISAR-DESIRE–II (TLR 16.6% after
treatment of DES-ISR with sirolimus-eluting stents and
14.5% after treatment with paclitaxel-eluting stents) (4) and
in the study done by Steinberg et al. (3) (TVR 22.2% after
DES treatment of DES-ISR vs. 10.3% for BMS-ISR).
These previous observations supported the notion that
DES-ISR is a particularly resistant lesion with high cardiac
event rates after percutaneous retreatment. The excellent
outcome in our small DES-ISR subgroup has to be
Table 5. Baseline Characteristics of Pooled BMS-ISR and
DES-ISR Patients*
Baseline Measures
BMS-ISR Subjects
(n ¼ 196)
DES-ISR Subjects
(n ¼ 70) p Value
Figure 1. Continued
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911interpreted cautiously. It is, however, conceivable that the R-
ZES is more effective than ﬁrst-generation DES or DEB in
the therapy of DES-ISR because a very effective anti-
proliferative compound was applied without apposition of
another thick metal/polymer layer but with preserved stent
scaffolding.
Regarding the Kaplan-Meier curves of the cumulative
incidence in TLR, there was a continuous rise of events
during the entire observation period in the ISR cohort.Table 4. Multivariate Predictors of TLF to 2 Years
Population Odds Ratio p Value
Total
ISR 1.856 <0.001
Prior CABG 1.758 <0.001
Bend 45 1.382 0.010
Previous myocardial infarction 1.293 0.040
Unstable angina 1.273 0.040
Pre-procedure RVD, mm 0.801 0.050
ISR
Prior CABG 4.195 <0.001
Unstable angina 2.516 0.009
Age, yrs 0.963 0.021
Abbreviations as in Tables 1 to 3.Nevertheless, this increase did not seem to be overpropor-
tional compared with the non-ISR cohort, though a late
catch-up phenomenon cannot be entirely excluded (16,17).Age, yrs 65.5  10.4 (196) 65.6  10.6 (70) 0.878
Male 75.0 (147/196) 82.9 (58/70) 0.180
Prior MI 52.6 (103/196) 51.4 (36/70) 0.872
Prior PCI 98.5 (193/196) 98.6 (69/70) 0.952
Diabetes mellitus 29.1 (57/196) 32.9 (23/70) 0.554
Insulin-dependent 10.2 (20/196) 12.9 (9/70) 0.541
ACS, % 45.4 (89/196) 45.7 (32/70) 1.000
Vessel location 0.921
LAD 36.6 (97/265) 35.6 (32/90)
LCX 23.4 (62/265) 23.3 (21/90)
RCA 34.0 (90/265) 35.6 (32/90)
Left main 1.1 (3/265) 2.2 (2/90)
SVG 4.2 (11/265) 3.3 (3/90)
Arterial graft 0.8 (2/265) 0.0 (0/90)
Values are mean  SD (N) or % (n/N). *3 patients with both BMS-ISR and DES-ISR are excluded.
ACS ¼ acute coronary syndrome; MI ¼ myocardial infarction; other abbreviations as in
Tables 1 to 3.
Table 6. Clinical Outcomes at 2 Years of Pooled BMS-ISR and DES-ISR
Patients
Safety Measures
BMS-ISR
(n ¼ 192)
DES-ISR
(n ¼ 69) p Value*
TVF 19.3 (37) 18.8 (13) 0.995
TLF 17.2 (33) 18.8 (13) 0.761
Death 5.7 (11) 5.8 (4) 0.939
Cardiac death 3.1 (6) 2.9 (2) 0.975
Cardiac death or TVMI 7.3 (14) 7.2 (5) 0.985
TVMI 5.2 (10) 4.3 (3) 0.664
Clinically driven TLR 12.5 (24) 13.0 (9) 0.990
Clinically driven TVR 14.6 (28) 14.5 (10) 0.939
MACE 19.8 (38) 21.7 (15) 0.813
Stent thrombosis, ARC def/prob 3.1 (6) 1.4 (1) 0.452
Early, 30 days 1.0 (2) 0.0 (0) 0.231
Late, >30 and 360 days 1.6 (3) 1.4 (1) 0.948
Very late, >360 days 0.5 (1) 0.0 (0) 0.434
Values are % (n). Three patients with both BMS-ISR and DES-ISR are excluded. *p Value is
adjusted to propensity score with the following baseline variables as independent variables:
age, sex, current smoker, prior percutaneous coronary intervention, hyperlipidemia, diabetes,
hypertension, prior myocardial infarction, prior bypass surgery, unstable angina or myocardial
infarction, left anterior descending artery, B2/C lesion, moderate/severe calciﬁcation, bend
>45 , Thrombolysis In Myocardial Infarction ﬂow grade 3, reference vessel diameter, lesion
length, and percent diameter stenosis.
Abbreviations as in Tables 2 and 3.
Richardt et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 9 , 2 0 1 3
Resolute Coronary Stent in Patients With ISR S E P T E M B E R 2 0 1 3 : 9 0 5 – 1 3
912Study limitations. Although our study is based on high-
quality data, the investigation has all the limitations of
a non–pre-speciﬁed, post hoc analysis. For instance, no
classiﬁcation of ISR morphology was done, which could
have been important for the comparison of ISR in BMS and
DES patients, and the number of DES-ISR patients
remains low. Furthermore, the present patient-based anal-
ysis limits the ability to evaluate outcomes related strictly to
ISR lesions. It is unusual to pool the results of a randomized
trial with that of a registry. Nevertheless, this variable has
been included in the multivariate analyses, and no signiﬁcant
interactions have been observed.Conclusions
The use of an R-ZES for treatment of ISR was safe, with
rates of CD, MI, and ST in line with the overall 2-year
events of both clinical trials. Rates of revascularization were
higher in ISR compared with non-ISR patients. TVR and
TLR rates of the R-ZES, however, are very persuasive in the
perspective of other ISR trials. Thus, R-ZES offers an
effective alternative for treatment of both BMS-ISR and
DES-ISR in this challenging subset of patients.Acknowledgments
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